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ABSTRACT 
Background: 18F-FDG PET image-derived parameters, such as standardized uptake 
value (SUV), functional tumor length (TL) and volume (TV) or total lesion glycolysis 
(TLG) may be useful for determining prognosis in patients with esophageal 
carcinoma. The objectives of this work were to investigate the prognostic value of 
these indices in esophageal cancer patients undergoing combined chemo-
radiotherapy treatment and the impact of TV delineation strategies. Methods: 45 
patients were retrospectively analysed. Tumors were delineated on pretreatment 18F-
FDG scans using adaptive threshold and automatic (FLAB) methodologies. SUVmax, 
SUVpeak, SUVmean, TL, TV, and TLG were computed. The prognostic value of each 
parameter for overall survival was investigated using Kaplan-Meier and Cox 
regression models for univariate and multivariate analyses respectively. Results: 
Large differences were observed between methodologies (from -140% to +50% for 
TV). SUV measurements were not significant prognostic factors of overall survival, 
whereas TV, TL and TLG were, irrespective of the segmentation strategy. After 
multivariate analysis including standard tumor staging, only TV (p<0.002) and TL 
(p=0.042) determined using FLAB were independent prognostic factors. 
Conclusions: Whereas no SUV measurement was a significant prognostic factor, 
TV, TL and TLG were significant prognostic factors of overall survival, irrespective of 
the delineation methodology. Only functional tumor volume and length derived using 
FLAB were independent prognostic factors, highlighting the need for accurate and 
robust PET tumor delineation tools for oncology applications. 
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1. Introduction 
The incidence of esophageal cancer is increasing and despite advances in 
therapy, the diagnosis still carries a poor prognosis (1). As with all tumors, the 
outcome for patients is strongly associated with the stage at initial diagnosis. The 
TNM (Tumor, Node, Metastasis) system currently in use for the staging of 
esophageal cancer does not take into account non-anatomical factors such as 
histopathologic type, grade or various biomarkers that may be important 
determinants of prognosis. The pathologic stage is given by surgery but this 
procedure is not possible for all patients because it is associated with a high risk of 
mortality and morbidity. Therefore a non-invasive staging method would be of great 
interest, and within this context the primary role of 18F-FDG positron emission 
tomography (PET) in esophageal cancer is the detection of distant metastases (2-4). 
This modality is also gaining acceptance in esophageal cancer for the assessment of 
therapy response (5-6) or for radiotherapy treatment planning (7-9). Lately, some 
authors also suggested that different parameters derived from initial 18F-FDG PET 
images could have a role as independent prognostic factors (10-14). Studied 
parameters include standardized uptake value (SUVmax as the maximum uptake in 
the primary tumor or in the combined primary and regional area), tumor functional 
longitudinal length (TL), tumor functional volume (TV), nodal uptake or FDG avid 
metastases (10-14). Although a few studies have demonstrated the interest of these 
indices for determining prognosis, there are conflicting results concerning the 
independent prognostic value of each of these indices. For example, Hyun et al (12), 
analyzing results from 151 patients with principally squamous cell carcinoma (SCC), 
have recently suggested that primary tumor SUVmax is not an independent prognostic 
factor, in agreement with other studies (10,15,16). On the other hand, Kato et al (17) 
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based on the analysis of 184 patients with esophageal SCC have shown that SUVmax 
of the primary tumor is an independent prognostic factor of overall survival, in 
agreement with other studies (18-20). These conflicting results can be potentially 
caused by differences in the methodology used for the analysis of the PET images. 
Although SUVmax is less sensitive to tumor size, the conflicting results considering its 
value as an independent prognostic factor may also be due to variability in the tumor 
sizes considered in the different studies.  
Pathological TL has been shown to be an independent prognostic factor in 
esophageal carcinoma (21). Therefore determining the functional TL in 18F-FDG PET 
images may be a good surrogate. The use of different thresholds for the 
determination of the functional TL in the existing studies may be responsible for the 
conflicting results regarding its value as a predictor of response to chemo-
radiotherapy (11,22), while it has been shown as an independent predictor in patients 
undergoing surgery (10). On the other hand, functional TV may be more 
representative of overall tumor burden. The value of the functional TV has been only 
recently explored in a single study of patients with esophageal carcinoma considering 
a heterogeneous treatment regime (76% and 24% treated by surgery and combined 
radio-chemotherapy respectively) (12). In this study both the presence of metastases 
and the TV were found to be independent prognostic factor of patient overall survival.  
Tumors were delineated based on a three fixed threshold scale depending on the 
tumor SUVmax. Although such an approach may be simple to implement in clinical 
practice the use of fixed threshold for functional TV determination suffers from 
multiple shortcomings which have been highlighted in different studies (23,24). In 
addition, the proposed scale is not universally applicable to the different clinical 
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settings spanning from the acquisition protocols to the scanning systems used and 
variable associated image qualities. 
Therefore despite early evidence that functional TL and TV may be useful 
parameters in predicting survival and response to therapy there is a clear need in 
assessing the influence of the methodology used in obtaining these indices. Finally, 
the determination of functional TV may allow the calculation of alternative image 
derived indices such as the total glycolytic lesion index (TLG) (g), defined as the 
product of the TV (ml) and its associated mean activity (SUVmean) (g/ml) (25), whose 
value has not as yet been explored in predicting response to therapy or as prognostic 
factor of survival using 18F-FDG in esophageal carcinoma. 
The objective of this study was therefore to retrospectively investigate the 
prognostic value of 18F-FDG PET in 45 esophageal cancer patients treated with 
concomitant radio-chemotherapy, considering for the first time in a single study all of 
the commonly-used PET-derived parameters such as functional TL, TV, SUV 
measurements (max, peak, mean) and TLG. In addition the impact of different tumor 
delineation strategies was assessed.  
 
2. Materials and Methods 
2.1 Patients 
 45 patients with a newly diagnosed esophageal cancer treated between 2004 
and 2008 with concomitant radio-chemotherapy and without surgery were included in 
this study. The characteristics of the patients are given in table 1. 41 patients were 
male (91%), and the mean age at the time of diagnosis was 66±10 years. Most of the 
tumors were squamous cell carcinoma (73%) and originated from the middle and 
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lower esophagus (76 %). All patients were referred before treatment for an 18F-FDG 
PET study as part of a routine procedure for the initial staging in esophageal cancer. 
The treatment included three courses of 5-fluorouracil/cisplatin and a median 
radiation dose of 60Gy given in 180cGy daily fractions delivered once daily, 5 days a 
week for 6-7 weeks. Follow-up data were prospectively collected in a database for 
further analysis and overall survival was calculated. The current analysis was carried 
out after an approval by the institutional ethics review board. 
 
2.2 18F-FDG PET acquisitions 
18F-FDG PET studies were carried out prior to the treatment. Patients were 
instructed to fast for a minimum of 6h before the injection of 18F-FDG. The 
administered dose was 5 MBq/kg, and static emission images were acquired (2min 
per bed position) from head to thigh beginning 60 minutes after injection on a Philips 
GEMINI PET/CT system (Philips Medical Systems, Cleveland, OH USA). In addition 
to the emission PET scan, a low dose CT scan without IV or oral contrast was 
acquired for attenuation-correction. Images were reconstructed with the RAMLA 3D 
algorithm using standard clinical protocol parameters: 2 iterations, relaxation 
parameter of 0.05, a 5mm 3D Gaussian post-filtering, and a 4x4x4mm3 voxels grid 
sampling. 
 
2.3 PET image analysis 
The following parameters were extracted from each PET image: SUVmax, 
SUVpeak defined as the mean of SUVmax and its 26 neighbors, mean SUV within the 
delineated tumor (SUVmean), functional TL in longitudinal direction, functional TV, and 
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TLG. SUVpeak, usually defined as a 1cm circle or sphere (26) (we used a 3x3x3 cube 
of 4x4x4 mm3 voxels which roughly corresponds to the same ROI), was considered 
in order to investigate the impact of reducing the potential bias in the SUVmax 
measurements as a result of its sensitivity to noise.   
Whereas SUVmax and SUVpeak are independent on the tumor delineation 
strategy used, TL, TV, SUVmean and the derived TLG were determined on 
delineations performed using two strategies. First, an adaptive threshold (23) using a 
background region of interest (ROI) manually chosen by two experienced nuclear 
medicine physicians led to two different results Tbckgrd
1 and Tbckgrd
2. Observers were 
instructed to choose the ROI in the mediastinum at a sufficient distance from the 
lesion to avoid any overlapping. However, they were allowed to choose the size, 
shape and exact placement of the ROI. Finally the automatic Fuzzy Locally Adaptive 
Bayesian (FLAB) algorithm (24,27) was considered. 
2.4 Statistical analysis 
All quantitative data were expressed as mean±1 standard deviation (SD) and 
summary statistics are given in table II.  
The correlation between all parameters extracted using the different 
methodologies was computed with Pearson coefficients. The differences between 
methodologies were assessed using Bland-Altman analysis (28) to define bias as the 
mean error, and agreements intervals (upper and lower limits) as 1.96 times the SD. 
Kaplan-Meier methods were used to estimate the survival distributions (29). Overall 
survival was calculated from the date of initial diagnosis to the date of death or most 
recent follow-up in case of patients still alive. For each considered parameter, 
survival curves were generated. The most discriminating threshold value allowing 
differentiation of the two groups of patients was selected using receiver operating 
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characteristic (ROC) methodology (30). Prognostic value of each parameter in terms 
of overall survival was assessed by the log-rank test. The significance of the following 
factors were tested: age, gender, histology type, T, N, M classifications, AJCC 
(American Joint Committee on Cancer) stage (31), TL, TV, SUVmax, SUVpeak, , 
SUVmean, and TLG. Independent prognostic factors of overall survival were 
determined using multivariate Cox regression analysis (32) by incorporating in the 
model all parameters that were deemed significant in the univariate analysis. 
However, the indices obtained by each delineation (Tbckgrd
1, Tbckgrd
2 and FLAB) were 
incorporated in the multivariate analysis separately since they were found to be 
highly correlated (Pearson r>0.8, r2>0.66 ; see results section 3.1). All tests were 
carried out using MedCalcTM (MedCalc Software, Belgium). P values <0.05 were 
considered statistically significant. 
 
3. Results  
All primary lesions were detected by 18F-FDG PET. The intensity of maximum 
18F-FDG uptake in the primary lesion was quite high with a normally distributed 
SUVmax of 10±3.8. As expected, SUVpeak measurements were comparatively lower 
(8±3). Measurements related to the dimensions of the tumors were less uniformly 
distributed than SUV measurements, with a larger SD with respect to the mean. For 
example the TV(FLAB) was 35±33cm3. 
 
3.1 Correlation between image derived indices and between methodologies 
TL measurements were correlated with TV (p<0.0001) although with moderate 
coefficients (r=0.69, 0.58 and 0.6 for FLAB, Tbckgrd
1 and Tbckgrd
2 respectively). No 
significant correlation was found between any SUV measurement (SUVmax, SUVpeak, 
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SUVmean) and TV (p>0.2, r<0.3), irrespective of the delineation strategy, in line with 
results of other studies such as Van Heijl et al (33). 
All SUVmean measurements derived from TV delineation performed using the 
two different methodologies considered were highly correlated (p<0.0001) with 
coefficients >0.97. TV (r>0.82), TL (r>0.91) and TLG (r>0.95) results were also highly 
correlated (p<0.0001) for both methodologies. 
Despite high correlation coefficients, large differences were observed for 
several patients between measurements using the two delineation methodologies 
considered, and between the two users of the same adaptive thresholding. Figure 
1(A-B) illustrates such differences. In the case of adaptive thresholding these 
differences were the result of the two users placing differently the background ROI. 
A summary of the Bland-Altman analysis carried out to compare the 
delineation methods and highlight potential differences is presented in figure 2(C-D) 
and complete results are given in table III. The largest differences between 
methodologies were observed for TV with a bias of up to 50% between the 
adaptative thresholding and FLAB: both users resulted in globally smaller volumes 
(bias of -50%±50% and -21%±54% for Tbckd
1 and Tbckd
2 respectively). Agreement 
intervals (upper and lower limits) were large for all parameters and for all 
comparisons, up to +80% and -140% (see fig.2B). Even between the two users of the 
same adaptive thresholding method (see fig.2A), mean differences of -30±35% were 
seen and limits of agreement were large, from -100 to +45%. No significant trend was 
found regarding the correlation between TV and differences between methodologies 
(r<0.2, p>0.1). 
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Better agreement was observed for TL and SUVmean, however intervals of 
agreement were large (-50% to -25% lower limit and +20% to +40% upper limit for 
TL; -80% to -10% lower limit and +10 to +80% upper limit for SUVmean). 
Due to the combined effect of TV and SUVmean, TLG differences were in 
between, with moderate bias but still large agreement intervals (upper and lower 
limits of -120% to -75% and +40% to +90% respectively). 
 
3.2 Survival analysis 
At the time of last follow-up, 10 patients were alive with no evidence of 
disease, 9 were alive with recurrent esophageal cancer and 26 had died from the 
disease. With a median follow-up of 60 months (range 9-82), the overall median 
survival was 15 months. The 1-year and 2-year survival rates were 63% and 34% 
respectively.  
The results of the log-rank analysis of significant parameters for overall 
survival in univariate analysis are given in table IV. Table V summarizes the 
prognostic value of all the parameters under investigation in this study. 
Age, gender, and histology types were not significant prognostic factors in the 
univariate analysis. Neither were T and N classifications. In the univariate analysis, 
the presence of metastases (median survival of 26 months (M0) versus 12 months 
(M1), p=0.01)) and the clinical AJCC stage (p<0.001) were significant prognostic 
factors.  
Although there was a trend observed, neither SUVmax nor SUVpeak were 
significant prognostic factors. A SUVmax <5 or <8 tend to be a factor of better 
outcome with a median survival of 14 vs. 7 months (p=0.08) or 21 vs. 13 months 
(p=0.1) respectively (see fig.3A). 
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Mean SUVs in the tumor were not significant prognostic factors in univariate 
analysis. There was however a trend for shorter survival associated with higher 
SUVmean. For example the median survival reduced by a factor of 2 for patients with a 
SUVmean higher than 5 (13 months vs. 21 months, p=0.06). This was however 
observed only when the FLAB methodology was used to define TV, while no similar 
trend was observed with SUVmean parameters obtained with adaptive thresholding. 
Functional TV was a significant prognostic factor of overall survival, whatever 
methodology was used (p<0.001 using FLAB, and p=0.004 for both Tbckgrd
1 and 
Tbckgrd
2, see figure 3(B-C)). In addition, using the TV, and independently of the 
delineation approach used, allowed to separate our population into 3 groups with 
significantly different outcome (p=0.002, p=0.02 and p=0.004 for FLAB, Tbckgrd
1 and 
Tbckgrd
2 respectively). For instance, volumes defined by FLAB less than 14cm3, 
between 14 and 85cm3 or superior to 85cm3 were respectively associated with a 
median survival of 49 (19 patients), 15 (21 patients) and 5.5 (6 patients) months as 
illustrated in figure 3(D). In figure 4(A-C) three examples of 18F-FDG PET baseline 
images of patients belonging to each of these three groups are presented.  
Functional TL was also a significant prognostic factor with results similar to TV 
(p=0.01, p=0.02 and p=0.04 for FLAB, Tbckgrd
1 and Tbckgrd
2 respectively), apart from 
not being possible to significantly differentiate 3 groups of patients with different 
outcome, independently of the strategy. 
Similarly, TLG was also a significant prognostic factor whatever methodology 
was used, while it was equally not possible to significantly differentiate three groups. 
Median overall survival was 10 months for patients with a TLG (FLAB) >180g, and 
increased to 21 months for patients with a TLG<180g (p=0.01). Similar results were 
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After multivariate analysis, considering each delineation methodology 
separately only TV obtained using FLAB and AJCC stage were found to be 
independent significant prognostic factors (p=0.0017 and 0.0021 for TV and AJCC 
respectively), whereas only AJCC stage was an independent significant prognostic 
factor (p<0.002) when considering TV obtained by adaptive thresholding.  
Similar results were obtained when replacing TV by TL, with both TL and 
clinical AJCC staging found to be independent significant prognostic factors in the 
case of FLAB (p=0.017 and p=0.042 for AJCC stage and TL respectively), whereas 
in the case of adaptive thresholding only AJCC staging was an independent 
significant prognostic factor (p=0.0021). 
On the other hand, in the case of TLG only the AJCC staging was an 
independent significant prognostic factor (p<0.002), whatever delineation strategy 
was considered.  
4. Discussion  
An accurate staging in esophageal cancer is essential for guiding therapy. The 
standard conventional modalities are endoscopic ultrasonography and computed 
tomography even if this combined approach suffers from several shortcomings. 18F-
FDG PET is more and more often included in the initial staging because it allows a 
more accurate disease assessment, especially regarding the detection of distant 
metastases (2-4). Since no patient underwent surgery in our study, 
anatomopathology data were not available. Therefore T,N,M classifications and 
AJCC stages were determined using suboptimal conventional staging and this could 
explain the poor prognostic value of T or N classification in our population. 
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As found in our study, 18F-FDG uptake is always present in esophageal cancer if 
extended at least to submucosa (34). Some authors suggested that the intensity of 
18F-FDG uptake could be related to prognosis in esophageal cancer, based on the 
good correlation existing between hexokinase activity or poor differentiation and 
tumor uptake (35) and also because increasing SUVmax values seem to correlate with 
T classification, which is part of the TNM staging (36).  
In our study, SUV measurements were not significant prognostic factors of overall 
survival. While various cut-off values of SUVmax tend to be associated with a poor 
prognosis, none led to statistically significant differentiation. Swisher et al. reported 
similar results in a uniform group of highly selected patients with locally advanced 
esophageal cancer treated by neoadjuvant radiochemotherapy (37). On the other 
hand, these results could appear in contrast with our previous report (18), where we 
initially reported that a SUVmax cut-off value of 9 had an independent prognostic value 
of overall survival, but this difference may be explained by the different patient 
characteristics considered in the two studies. We previously considered (18) a daily 
practice population, half of which underwent curative surgery, while we included here 
only patients with advanced disease exclusively treated by combined radio-
chemotherapy. 
TL established by pathological examination has been demonstrated to be an 
independent prognostic factor of long term survival (21). Some authors proposed 
estimating TL based on 18F-FDG PET images using different thresholds (38). 
Functional TL has been studied as a predictor of response to neoadjuvant 
chemoradiotherapy with conflicting results (11,22). In a group of 69 patients with 
esophageal squamous cell carcinoma undergoing curative surgery, Choi et al. 
demonstrated that functional TL was an independent prognostic factor (10). However, 
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one may argue that functional TL is a parameter that does not reflect the real volume 
of the tumor but only its longitudinal extension and could be therefore considered as 
only a surrogate of tumor spatial extent. This argument can be supported by the data 
shown in this work, where only a moderate correlation (r<0.7) was found between TV 
and TL, suggesting that functional TV may be more accurate in assessing actual 
tumor burden. In our study we also compared the prognostic value of TL with that of 
TV. Both parameters were found to be significant prognostic factors irrespective of 
the functional volume delineation strategy. In addition, both TV and TL were 
independent prognostic factors of survival in the multivariate analysis. However, this 
result was found to be dependent on the segmentation algorithm, with both 
parameters being independent survival prognostic factors only when determined 
using the automatic FLAB segmentation. This may be related to the higher overall 
accuracy of FLAB with respect to adaptive thresholding for tumor delineation as 
previously reported (24,27,39). Despite the similar prognostic values of TL and TV, 
only TV allowed a statistically significant stratification of patients into three groups, 
irrespective of the segmentation methodology. More specifically, two different cut-off 
values (85 and 14cm3) resulted in significant differentiation of two groups among the 
patients with median overall survival of 5 to 6 vs 20 months (p=0.0005) and 49 vs 13 
months (p=0.036) for 85 and 14cm3 respectively. Being able to provide such a finer 
stratification of patient groups could be of value in clinical trials assessing new 
therapeutic regimes.    
SUVmean measured in a volume determined using the different tumor delineation 
approaches considered was not found to be a prognostic factor of overall survival, 
although a trend was seen for SUVmean associated with TV defined with FLAB, which 
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tended to differentiate patients with poor and better prognosis (13 vs 21 months, 
p=0.06).  
A fundamental biological question underlying 18F-FDG PET prognostic value is 
whether the total volume or the metabolic active portion of the tumor is most 
important. Intuitively both would seem important and desirable to determine. In our 
study, both functional TL and TV (representative of the tumor functional spatial 
extent) were significant prognostic factors compared to SUVmean (representative of 
the tumor glycolytic metabolism) which was not. Combining both parameters into total 
lesion glycolysis index (TLG) was a prognostic factor of overall survival whatever 
methodology was used for tumor delineation. However it was not an independent 
significant prognostic factor in the multivariate analysis. Only very few data are 
available on the potential clinical value of TLG in different cancer models. Xie et al 
reported on prognostic value of TLG in head and neck cancer for long term survival 
(40), while Cazaentre et al. demonstrated the usefulness of TLG for predicting 
response to radioimmunotherapy in lymphoma (41). To date, the limited use of TV 
and TLG in clinical studies could be explained by the poor accuracy, robustness and 
reproducibility of available tumor delineation tools affecting the clinical value of 
resulting measurements. The fact that TLG was not an independent prognostic factor 
whereas TV alone was, suggests that the prognostic value of TLG mainly comes 
from the volume information and is impaired by the low prognostic value of SUVmean 
measurements. In addition, the value of TLG might be reduced by a loss of 
information when combining the TV and the SUVmean into one parameter by simple 
product, since large tumors with low uptake might result in the same TLG as small 
tumors with high uptake. Finally, the lack of partial volume effects (PVE) correction 
might also play a role in the reduced prognostic value of all SUV measurements as 
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well as the resulting TLG, since tumor volumes across the patients range from quite 
small and significantly affected by PVE (<2cm in diameter) to very large tumors for 
which PVE have smaller quantitative impact. 
As expected, results concerning parameters dependent on the tumor delineation 
process were well correlated. On the other hand our results also highlighted the 
potential impact of differences between existing tumor delineation methods, with TV 
and TL being independent survival prognostic factors only when determined using 
FLAB. This approach has been previously shown to be both robust and accurate 
(24,27). At present most commonly used methods are based on fixed or adaptive 
thresholds. Fixed thresholding has been demonstrated to be both inaccurate and 
non-robust (23,24,27,39) and was therefore not considered in this study.  
Regarding the adaptive thresholding performance, results from one observer 
(Tbckgrd
2) were closer to these of FLAB compared to the other one (Tbckgrd
1), with 
however significant differences, as shown in figure 2B and table III. Neither 
TV(Tbckgrd
1) nor TV(Tbckgrd
2) were independent prognostic factors contrary to 
TV(FLAB). This can be explained by the behavior of adaptive thresholding 
(independently on the user) for several tumors. Most of the tumors exhibited simple 
shapes and homogeneous tracer uptake. However some were more complex and 
exhibited higher heterogeneity, or were small (<2-3cm) with low contrast. Adaptive 
thresholding has been demonstrated to provide unsatisfactory delineation for such 
cases (24), because its final threshold is based on the ratio between an isocontour at 
70% of the maximum and the background ROI. Such isocontour tends to 
overestimate (respectively underestimate) the actual value of the entire tumor for 
heterogeneous uptake (respectively small tumors will low contrast).  
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Hence the adaptive thresholding led to significant under-evaluation of larger 
heterogeneous tumors in our study, e.g. a patient with a survival of 6 months had a 
TV defined by FLAB of almost 97cm3, whereas TV(Tbckgrd
1) and TV(Tbckgrd
2) were 
38cm3 (-61%) and 50cm3 (-50%) respectively, clearly missing parts of the tumor. On 
the other hand, the dependency on the background ROI is higher regarding small 
tumors with low contrast, e.g. for a patient with 21 months survival, TV(FLAB) was 
5.8cm3, whereas TV(Tbckgrd
1) and TV(Tbckgrd
2) were 1.9cm3 (-67%) and 26.9cm3 
(+364%) respectively. Several patients were therefore incorporated in the wrong 
survival curve, mostly patients with large volumes that were underestimated by the 
adaptive threshold. 
In addition, adaptive thresholding was found to be highly user dependent, since 
we observed a bias up to 30% between the two users measuring TV, the agreement 
interval being too large for clinical applications (-110% to +45%). This seems to be in 
agreement with results concerning the level of reproducibility in measuring functional 
TV from 18F-FDG imaging which can vary from 21% to 90% using automatic and 
threshold-based approaches respectively (42). If advanced segmentation algorithms 
are not available, the use of adaptive thresholding approaches should be preferred to 
manual or fixed threshold-based delineation. Automated background ROI 
determination could reduce the inter observer variability observed in this work. 
The limits of this study are its retrospective nature and the limited number of 
patients. Our results need to be confirmed through a prospective study on a larger 
cohort of patients. It is finally worth noting that overall survival might have been 
affected by other factors such as subsequent treatment for patients who relapsed, 
although this should have minor impact to the results of this study since it applies to 
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all considered parameters. Other outcome measures such as progression-free 
survival were not investigated in this study. 
 
 5. Conclusion 
Our results suggest that the functional tumor volume followed by length has 
additional value compared to commonly-used SUV measurements (SUVmax, SUVpeak, 
SUVmean) for prognosis in patients with locally advanced esophageal cancer treated 
with exclusive concomitant radio-chemotherapy. Both parameters were significant 
prognostic factors of overall survival, independently of the approach used to 
delineate the tumors. However, only the automatic FLAB algorithm allowed TV and 
TL to be independent prognostic factors of survival in a multivariate analysis that 
included standard tumor staging. In addition the total lesion glycolysis index was a 
statistically significant, but not independent, prognostic factor irrespective of the 
delineation algorithm used. Our findings confirm the potential value of 18F-FDG PET 
to give a useful orientation for patient management purpose in esophageal cancer 
but they also highlight the influence of the methodology used on the degree of 
pertinence of these PET image derived parameters of interest as their accuracy and 
their clinical significance increase if they are computed using more reliable and 
robust tumor segmentation methods. 
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Figures captions 
Fig.1: Illustration of differences in tumor delineation depending on the methodology 
for (A) a small (<8cm3) and low contrast (approximately 2:1) and (B) a larger (30cm3) 
and higher contrast (approximately 7:1) tumors. 
 
Fig.2: Bland-Altman analysis of differences between (A) Tbckgrd
1 and Tbckgrd
2 and (B) 
Tbckgrd and FLAB, for each parameter (TL, TV, SUVmean, TLG). Grey columns and 
error bars represent the mean differences (bias) and associated standard deviation 
respectively. Bold arrows up and down denote upper and lower limits respectively. 
95% confidence intervals for each are given in table III. 
 
Fig.3: Kaplan-Meier survival curves obtained using (A) SUVmax, TV measured by (B) 
FLAB and (C) Tbckgrd
1, and (D) defining 3 groups using TV measured by FLAB. 
 
Fig.4: 18F-FDG PET images (axial, coronal and sagittal views from top to bottom) of 
patients with a (a) small tumor (11cm3, 54 months survival), (b) medium size tumor 




Table I: Patient demographic and clinical characteristics 
Table II: Parameters definition and statistics. 
Table III: Bland-Altman analysis results comparing delineation strategies for all 
parameters. 
Table IV: Parameters with significant prognostic value after univariate analysis. 
















Parameter # of patients (%) 
Gender  
  Male 41(91) 
  Female  4(9) 
 
Age  
  Range 45-84 
  Median 68 
 
Site  
  Upper esophagus 11(24) 
  Middle esophagus 17(38) 
  Lower esophagus 17(38) 
 
Histology type  
  Adenocarcinoma 12(27) 
  Squamous cell carcinoma   33(73) 
  
  
Histology differentiation  
  Well differentiated 12(27) 
  Moderately differentiated 11(24) 
  Poorly differentiated 4(9) 
  Unknown 18(40) 
 
TNM Stage  
           T1 6(13) 
           T2 7(16) 
           T3 22(49) 
           T4 10(22) 
           N0 18(40) 
           N1 27(60) 
           M0 29(64) 
           M1 16(36) 
 
AJCC Stage  
  I  3(7) 
  IIA  7(16) 
 IIB  5(11) 
 III 14(31) 
  IVa  5(11) 





Definition Notation Mean±SD Range 
Highest SUV within the tumor SUVmax 10±3.8 2.2 – 19.7 
 Mean of SUVmax and its 26 neighbors SUVpeak 8.2±3.3 1.8 – 16.1 
 
Mean SUV of 













) 6.2±2.7 1.6 – 13.8 















) 29.2±29.7 2.4 – 133.9 
FLAB TV(FLAB) 36.3±33.7 3.0 – 139.7 
Functional tumor 












) 5.6±2.9 1.6 – 14.4 














) 198.8±209.4 6.9 – 921.3 




















TL 6.7±18 1.3 to 12.1 -28.6 -37.9 to -19.3 41.9 32.6 to 51.2 
TV -29±37.3 -40.2 to -17.8 -102 -121.3 to -82.8 44.1 24.8 to 63.4 
SUVmean -6.3±9 -9 to -3.6 -23.9 -28.5 to -19.3 11.2 6.6 to 15.8 
TLG -23.5±32.3 -33.2 to -13.8 -86.8 -103.5 to -70.1 39.7 23 to 56.4 
 
Parameter 













 -5.9 ± 15.3 -10.4 to -1.4 -35.8 -43.6 to -28 24 16.2 to 31.8 
Tbckgrd
2




 -48.8 ± 48.8 -63.3 to -34.3 -144.5 -169.5 to -120 46.9 21.9 to 71.9 
Tbckgrd
2




 11.5 ± 36.2 0.7 to 22.2 -59.5 -78 to -41 82.4 63.8 to 100.9 
Tbckgrd
2




 -34.5 ± 25.6 -42 to -26.9 -84.6 -97.6 to -71.5 15.7 2.6 to 28.7 
Tbckgrd
2
 -10.6 ± 33.2 -20.4 to -0.7 -75.6 -92.5 to -58.6 54.4 37.5 to 71.4 
SD: Standard Deviation. CI: Confidence Interval. UL: Upper Limit. LL: Lower Limit. 
Table III
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AJCC stage 0.281 0.090 – 0.881 0.0008 26vs8 
M stage  0.402 0.172 – 0.940 0.01 26vs12 
TL(Tbckgrd
1
) 0.318 0.133 – 0.761 0.02 21vs10 
TL(Tbckgrd
2
) 0.393 0.164 – 0.939 0.04 21vs10 




0.212 0.020 – 2.280 0.004 16vs5 




0.212 0.020 – 2.280 0.004 16vs5 
N/A N/A 0.004 49vs14vs5  
TV(FLAB) 
0.236 0.050 – 0.909 0.0005 20vs5.5 
N/A N/A 0.002 49vs15vs5.5  
TLG(Tbckgrd
1
)  0.217 0.064 – 0.735 0.007 20vs8 
TLG(Tbckgrd
2 
) 0.202 0.063 – 0.645 0.01 20vs10 
TLG(FLAB)  0.337 0.147 – 0.772  0.02 21vs10 










prognostic factor in 
multivariate analysis 
Age No - 
Gender No - 
Histology type No - 
AJCC stage Yes Yes 
T No - 
N No - 
M Yes No 
SUVmax No - 
SUVpeak No - 
SUVmean(Tbckgrd
1
) No - 
SUVmean (Tbckgrd
2
) No - 
SUVmean(FLAB) No - 
TL(Tbckgrd
1
) Yes No 
TL(Tbckgrd
2
) Yes No 
TL(FLAB) Yes Yes 
TV(Tbckgrd
1
) Yes No 
TV(Tbckgrd
2
) Yes No 
TV(FLAB) Yes Yes 
TLG(Tbckgrd
1
)  Yes No 
TLG(Tbckgrd
2 
) Yes No 
TLG(FLAB)  Yes No 
 
Table V 
 
